Evidence map›Paper›PMID 23954846›Full record

ArticleNeuropsychopharmacology : official publication of the American College of Neuropsychopharmacology2014

Elevation of dopamine induced by cigarette smoking: novel insights from a [11C]-+-PHNO PET study in humans.

Bernard Le Foll, Mihail Guranda, Alan A Wilson, Sylvain Houle, Pablo M Rusjan, Victoria C Wing, Laurie Zawertailo, Usoa Busto, Peter Selby, Arthur L Brody and 2 more

Registry-linked trialOpen access · bronzeAbstract read
In one paragraph

Article in Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01721473 (Nicotinic Acetylcholine Receptor Density and Veteran Cigarette Smokers), which is not on this map. Cited by 40 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
40citing papers in PubMed, 1 pooled it
3.0field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT01721473 completednot on this map

Nicotinic Acetylcholine Receptor Density and Veteran Cigarette Smokers

TypeobservationalSponsorVA Office of Research and DevelopmentRan2012 to 2016Enrolled184ConditionsPositron Emission TomographyArmspositron emission tomography scan
3 · Its place in the literature

Who cites it

40 citing papers in PubMed, 1 synthesis or guideline pooled it, 64 citations in OpenAlex.

  1. Pooled it
  2. Nicotine Patch Alters Patterns of Cigarette Smoking-Induced Dopamine Release: Patterns Relate to Biomarkers Associated With Treatment Response.Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco · 2022
    Trial
  3. Article
  4. Tobacco Smoking Functional Networks: A Whole-Brain Connectome Analysis in 24 539 Individuals.Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco · 2025
    Article
  5. Article
  6. Article
  7. Article
  8. Recently Abstinent Smokers Exhibit Mood-Associated Dopamine Dysfunction in the Ventral Striatum Compared to Nonsmokers: A [11C]-(+)-PHNO PET Study.Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco · 2022
    Article
  9. Tobacco and nicotine use.Nature reviews. Disease primers · 2022
    Review
  10. Article
  11. Multimodal investigation of dopamine DNeuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2021
    Article
  12. Article
  13. Review
  14. Article
  15. Article
  16. Article
  17. Review
  18. Article
  19. Review
  20. Neurobiological Considerations for Tobacco Use Disorder.Current behavioral neuroscience reports · 2018
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 3 institutions in 2 countries.

Bernard Le Foll1] Translational Addiction Research Laboratory, Centre for Addiction and Mental Health, Toronto, ON, Canada [2] Alcohol Research and Treatment Clinic, Addiction Medicine Services, Ambulatory Care and Structured Treatments, Centre for Addiction and Mental Health, Toronto, ON, Canada [3] Campbell Family Mental Health Research Institute, Centre for Addiction and Mental Health, Toronto, ON, Canada [4] Department of Family and Community Medicine, University of Toronto, Toronto, ON, Canada [5] Department of Pharmacology, University of Toronto, Toronto, ON, Canada [6] Department of Psychiatry, Division of Brain and Therapeutics, University of Toronto, Toronto, ON, Canada [7] Institute of Medical Sciences, University of Toronto, Toronto, ON, Canada.
Mihail GurandaTranslational Addiction Research Laboratory, Centre for Addiction and Mental Health, Toronto, ON, Canada.
Alan A Wilson1] Campbell Family Mental Health Research Institute, Centre for Addiction and Mental Health, Toronto, ON, Canada [2] Department of Psychiatry, Division of Brain and Therapeutics, University of Toronto, Toronto, ON, Canada [3] Research Imaging Centre, Centre for Addiction and Mental Health, Toronto, ON, Canada.
Sylvain Houle1] Campbell Family Mental Health Research Institute, Centre for Addiction and Mental Health, Toronto, ON, Canada [2] Research Imaging Centre, Centre for Addiction and Mental Health, Toronto, ON, Canada.
Pablo M Rusjan1] Campbell Family Mental Health Research Institute, Centre for Addiction and Mental Health, Toronto, ON, Canada [2] Research Imaging Centre, Centre for Addiction and Mental Health, Toronto, ON, Canada.
Victoria C WingBiobehavioural Addictions and Concurrent Disorders Laboratory (BACDRL), Centre for Addiction and Mental Health, Toronto, ON, Canada.
Laurie Zawertailo1] Department of Pharmacology, University of Toronto, Toronto, ON, Canada [2] Clinical Neuroscience Program, Centre for Addiction and Mental Health, Toronto, ON, Canada [3] Addiction Program, Centre for Addiction and Mental Health, Toronto, ON, Canada.
Usoa BustoClinical Neuroscience Program, Centre for Addiction and Mental Health, Toronto, ON, Canada.
Peter Selby1] Department of Family and Community Medicine, University of Toronto, Toronto, ON, Canada [2] Department of Psychiatry, Division of Brain and Therapeutics, University of Toronto, Toronto, ON, Canada [3] Clinical Neuroscience Program, Centre for Addiction and Mental Health, Toronto, ON, Canada [4] Addiction Program, Centre for Addiction and Mental Health, Toronto, ON, Canada.
Arthur L BrodyDepartment of Psychiatry and Behavioral Sciences, University of California at Los Angeles (UCLA), Los Angeles, CA, USA.
Tony P George1] Department of Psychiatry, Division of Brain and Therapeutics, University of Toronto, Toronto, ON, Canada [2] Institute of Medical Sciences, University of Toronto, Toronto, ON, Canada [3] Biobehavioural Addictions and Concurrent Disorders Laboratory (BACDRL), Centre for Addiction and Mental Health, Toronto, ON, Canada.
Isabelle Boileau1] Campbell Family Mental Health Research Institute, Centre for Addiction and Mental Health, Toronto, ON, Canada [2] Department of Psychiatry, Division of Brain and Therapeutics, University of Toronto, Toronto, ON, Canada [3] Institute of Medical Sciences, University of Toronto, Toronto, ON, Canada [4] Research Imaging Centre, Centre for Addiction and Mental Health, Toronto, ON, Canada [5] Addiction Imaging Research Group, Centre for Addiction and Mental Health, Toronto, ON, Canada.
Centre for Addiction and Mental Health · CAUniversity of Toronto · CAUniversity of California, Los Angeles · US

Funding

Nicotine Receptor Density & Dopamine System Function in Smokers: Treatment EffectR01DA020872 · NIDA · BRENTWOOD BIOMEDICAL RESEARCH INSTITUTE · PI BRODY, ARTHUR · 2005 to 2013
$2.0M
Nicotinic Acetylcholine Receptor Density and Veteran Cigarette SmokersI01CX000412 · VA · VA SAN DIEGO HEALTHCARE SYSTEM · PI BRODY, ARTHUR · 2013 to 2017
–
CIHRCSRD VA I01 CX000412NIDA NIH HHS R01 DA20872
6 · The paper itself

Abstract

Positron emission tomography (PET) has convincingly provided in vivo evidence that psychoactive drugs increase dopamine (DA) levels in human brain, a feature thought critical to their reinforcing properties. Some controversy still exists concerning the role of DA in reinforcing smoking behavior and no study has explored whether smoking increases DA concentrations at the D3 receptor, speculated to have a role in nicotine's addictive potential. Here, we used PET and [(11)C]-(+)-PHNO ([(11)C]-(+)-4-propyl-3,4,4a,5,6,10b-hexahydro-2H-naphtho[1,2-b][1,4]oxazin-9-ol) to test the hypothesis that smoking increases DA release (decreases [(11)C]-(+)-PHNO binding) in D2-rich striatum and D3-rich extra-striatal regions and is related to craving, withdrawal and smoking behavior. Ten participants underwent [(11)C]-(+)-PHNO scans after overnight abstinence and after smoking a cigarette. Motivation to smoke (smoking topography), mood, and craving were recorded. Smoking significantly decreased self-reported craving, withdrawal, and [(11)C]-(+)-PHNO binding in D2 and D3-rich areas (-12.0 and -15.3%, respectively). We found that motivation to smoke (puff rate) predicted magnitude of DA release in limbic striatum, and the latter was correlated with decreased craving and withdrawal symptoms. This is the first report suggesting that, in humans, DA release is increased in D3-rich areas in response to smoking. Results also support the preferential involvement of the limbic striatum in motivation to smoke, anticipation of pleasure from cigarettes and relief of withdrawal symptoms. We propose that due to the robust effect of smoking on [(11)C]-(+)-PHNO binding, this radiotracer represents an ideal translational tool to investigate novel therapeutic strategies targeting DA transmission.

Indexed as

Positron-Emission TomographyAdultCarbon RadioisotopesCorpus StriatumFemaleHumansMaleMiddle AgedReceptors, Dopamine D3SmokingUp-RegulationYoung AdultCarbon RadioisotopesReceptors, Dopamine D3

Identifiers

PMID23954846
PMCPMC3870776
OpenAlexW2026718617

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.